RecruitingNot ApplicableNCT05898009

Contribution of Oncogenetics in Breast Cancer in Reunion Epidemiology of Breast Cancer in Reunion: Study of the Reunion Mutation on BRCA2


Sponsor

Centre Hospitalier Universitaire de la Réunion

Enrollment

300 participants

Start Date

Oct 19, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

In mainland France, breast cancer is the most common cancer in women, with an estimated incidence of over 58,000 new cases. Even if breast cancer is a cancer with a good prognosis, it is responsible for more than 12,000 deaths per year (first cause of death by cancer in women in France). Breast cancer is a multifactorial disease, which results from the interaction between environmental, lifestyle, hormonal and genetic risk factors. In Reunion, more than 400 cases of breast cancer are diagnosed annually. As in mainland France, it is by far the most common cancer in Reunionese women, and its incidence continues to increase significantly since the age-standardized incidence rate increased by 28% between 2007 and 2017 to establish at 64.2/100,000 AP. Two studies carried out in patients carrying mutations in the breast-ovary predisposition genes in Reunion, showed that more than 50% of patients carrying BRCA mutation have a mutation specific to the Reunion population on the BRCA2 gene. These two studies, which confirm the genetic specificities of Reunion already described in other pathologies (Mucoviscidosis or Friedreich's Ataxia), suggest that this mutation could have a significant frequency in patients with breast cancer. Thus, evaluating the prevalence of this mutation in patients with breast cancer in Réunion would make it possible to adapt the indications for access to the oncogenetics consultation and the associated preventive measures


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating the role of a genetic mutation in the BRCA2 gene that appears to be common in people from Réunion Island who develop breast cancer. The goal is to better understand the genetic causes of breast cancer in this specific population. **You may be eligible if...** - You live in Réunion and were diagnosed with a first or second breast cancer (in situ or invasive) during the study period - A second cancer is eligible if it is in the opposite breast, or occurred at least 5 years after the first - You have agreed to participate and are covered by social security **You may NOT be eligible if...** - Your breast condition is actually a lymphoma (a different type of cancer) - You are a minor or are under legal guardianship Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

GENETICblood sample for BRCA2 mutation detection

blood sample


Locations(1)

Mireille IRABE

Saint-Pierre, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05898009


Related Trials